Uncategorized
Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials
DEDHAM, Mass.--(BUSINESS WIRE)-- #EVP--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S. Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control